• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Celebrates 25 Years of Exceptional Patient Care, Empowering the Future of Kidney Health

    1/15/25 9:05:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email

    DENVER, Jan. 15, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care provider, is celebrating 25 years of clinical care delivery and leadership in healthcare innovation. Since forming with a purpose "to give life" in 2000, DaVita has focused its efforts to improve clinical outcomes, enhance quality of life for patients and be a force for positive change for the healthcare system. By fostering an inclusive, mission-driven workforce and building strong community partnerships, DaVita is helping empower the future of kidney health.

    DaVita's 25 years of clinical excellence is built on a steadfast commitment to patient-centered care — through purpose-driven clinical strategy, value-based programs, investments and research in new capabilities, and advancing and increasing access to treatment options.

    "Healthcare at its core is a service, provided by and for people. I'm proud of the immense progress we've made through our steadfast commitment to improving lives," said Javier Rodriguez, CEO for DaVita. "Together we will continue to push boundaries to create better outcomes for our patients and physician partners, as well as purpose-driven career opportunities for our teammates, today, tomorrow and every day as we look toward the next 25 years."

    A Legacy of Clinical Excellence

    Throughout the last 25 years, DaVita's teammates (employees) and its physician partners have made many contributions to the broader healthcare community, detailed on davitaforward.com. Highlights of these achievements demonstrate DaVita's commitment to helping revolutionize kidney care delivery:   

    • High-quality, personalized care for people living with chronic kidney disease (CKD) through higher quality standards, value-based care arrangements, home care, improved transplantation rates and more
    • Collaboration with the healthcare community, including physician partners, clinical researchers and pioneers of novel solutions, driving industry-wide innovation in pursuit of the best possible care for patients
    • Cultivation of a diverse and inclusive workplace that supports economic mobility for all of its teammates and to help address current nursing workforce challenges

    Recent Momentum Fuels DaVita Forward

    Over the past year, milestones in patient outcomes, care advancement, chronic health education and corporate citizenship demonstrate the momentum DaVita endeavors to bring into its next 25 years:

    • Improving Access to Kidney Health
      • When millions of lives were impacted by the devastation caused by Hurricanes Helene and Milton, DaVita and the kidney care community restored operations to the majority of dialysis centers within days of the storm relenting. DaVita deployed generators, water tankers, over 20,000 gallons of fuel, and high-water crews to conduct wellness checks and search for missing patients and teammates.
      • DaVita patients continue to dialyze at home in record numbers. In 2024, 15% of DaVita patients treated on a home modality, resulting in double digit home dialysis treatment growth.
      • Nearly 8,200 DaVita patients received a kidney transplant, the provider's highest number of annual transplants ever, in 2024.
      • The DaVita Health Tour provided free health screenings and chronic disease education to communities across the U.S.
      • DaVita and the American Diabetes Association (ADA) expanded their multi-year collaboration to advance chronic disease prevention, focusing on two prevalent chronic conditions in the U.S.: diabetes and chronic kidney disease.
      • MedSleuth's innovative BREEZE platform, which streamlines health information exchange between providers, transplant centers and patients to help accelerate progress through the waitlist process, has been implemented in 100% of DaVita centers in the U.S.
    • Enriching Healthy Communities Worldwide
      • DaVita expanded access to kidney care globally, now with operations in 14 countries, including recent expansions in Brazil and Colombia and new operations in Chile, Ecuador, and Japan.
      • DaVita's global operations are on track to be powered by 100% renewable energy through renewable energy purchases that match its electricity use in operations around the world. DaVita previously reached 100% renewable energy match in the U.S. in 2021.
      • DaVita has been recognized by USA Today, Newsweek, and TIME, among others, as a leading employer and a force for good.

    "DaVita stands as a testament to the power of values-driven care," stated Jeff Giullian, MD, chief medical officer for DaVita. "Our legacy is rooted in our uncompromising commitment to clinical excellence and innovation. We are not just improving care; we are transforming it, aiming to ensure that all people have access to care and can achieve their optimal health outcomes. We are building a future where excellence is the standard and a reality for all."

    To learn more about DaVita, please visit davita.com. To view an interactive timeline of the company's 25-year history, please visit davitaforward.com.

    About DaVita

    DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of September 30, 2024, DaVita served approximately 265,400 patients at 3,113 outpatient dialysis centers, of which 2,660 centers were located in the United States and 453 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

    Forward-Looking Statement

    This press release contains or refers to certain forward-looking statements within the meaning of the federal securities laws including, among other things. Without limiting the foregoing, statements including the words "expect," "intend," "will," "may," "continue," "target," "goal," "endeavor" and similar expressions are intended to identify forward-looking statements. The Company bases its forward-looking statements on information available to it on the date of this presentation, and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may otherwise be required by law. Actual future events could also differ materially due to numerous factors that involve substantial known and unknown risks and uncertainties including, among other things, the risks and uncertainties set forth under "Risk Factors" and elsewhere in the Company's reports on Form 10-K and Form 10-Q and the other risks and uncertainties discussed in any subsequent reports that the Company files with the Securities and Exchange Commission from time to time.

    Media Contact:

    DaVita Newsroom

    [email protected]

     

    DaVita 25th Anniversary Logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-celebrates-25-years-of-exceptional-patient-care-empowering-the-future-of-kidney-health-302351108.html

    SOURCE DaVita

    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:27 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Desoer Barbara J was granted 332 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:18 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:04 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

    DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, May 5, 2026 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the co

    4/20/26 2:06:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

    Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).For more than two dec

    3/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

    AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equit

    3/17/26 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.

    SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)

    3/26/26 5:39:34 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-K filed by DaVita Inc.

    10-K - DAVITA INC. (0000927066) (Filer)

    2/11/26 4:06:39 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    2/2/26 4:07:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

    11/1/22 9:18:39 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

    DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, May 5, 2026 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the co

    4/20/26 2:06:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

    DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, February 2, 2026Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen

    1/21/26 10:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care